Presentations from ISPOR and HTAi 2018

OHE staff recently attended ISPOR and HTAi international conferences. In this blog post, we share a selection of our presentations.

OHE staff recently attended ISPOR and HTAi international conferences. In this blog post, we share a selection of our presentations.

ISPOR

Comparing the EQ-5D-3L & EQ-5D-5L in a Cohort of Cancer Patients from Office of Health Economics

HTAi

The Role of HTA in Incentivising New Drugs and Vaccines to Tackle AMR from Office of Health Economics

Optimizing the Use of RWE in HTA: the ICER Membership Summit 2017 from Office of Health Economics

Optimising Risk-Based Screening: The Case of Diabetic Eye Disease from Office of Health Economics

Long-Term Evaluation of Broad Mental Health Interventions: A Review from Office of Health Economics

From evidence to action when people disagree: societal values and provision of end of life medicines from Office of Health Economics

Developing a value set for the EQ-5D-Y to support its use in HTA from Office of Health Economics

Multi-Stakeholder Dialogues Addressing Needs, HTA Requirements and Good Practices in Emerging Countries: The Asia-pacific Policy Forum from Office of Health Economics

Building Bridges Not Walls: Can We Develop Sustainable and Sharable Cost-Effectiveness Models? from Office of Health Economics

News & Insights

Latest Research & Publications

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

Are Recommendations for HTA of Gene Therapies Being Achieved?

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

Delivering the Triple Win: A Value-Based Approach to Pricing

All Publications

Presentations from ISPOR and HTAi 2018

Related News

How do we Get and Pay for New Antibiotics? Proposed New Models for Value Assessment and Contracting for Payment.

Price Transparency: Good or Bad? What Does Literature and Theory Tell Us?

Funding Challenges in the Malaysian Health Care System

OHE at HESG Winter 2020